Outcomes
Weight Regain After Tirzepatide
Weight regain after stopping tirzepatide is the expected outcome, not an unusual one. In SURMOUNT-4, participants randomised to placebo after losing weight during an open-label lead-in regained substantially over 52 weeks, while those who continued maintained their loss. The mechanism is the return of appetite signalling once the drug is withdrawn.
Key takeaways
- Regain after stopping is the expected outcome supported by randomised evidence.
- SURMOUNT-4's design isolates the drug's role, since all participants first lost weight on it.
- Regain is driven by returning appetite signalling, not by behavioural failure.
- The same pattern appears in semaglutide withdrawal trials, indicating a class effect.
- This finding should shape cost planning before treatment starts, not after.
| Primary evidence | SURMOUNT-4 (NCT04660643, PMID 38078870) |
|---|---|
| Design | Randomised withdrawal after 36-week open-label lead-in |
| Follow-up | 52 weeks post-randomisation |
| Participants | 670 |
| Finding | Substantial regain on placebo; maintenance on continued treatment |
| Class pattern | Consistent with semaglutide withdrawal data |
Why does the SURMOUNT-4 design matter so much?
Because it removes the usual objection to regain data. Observational follow-up after people stop can always be explained by selection — perhaps those who stopped were struggling anyway. SURMOUNT-4 randomised people who had all already succeeded on the drug, so the groups were comparable at the point of divergence. What follows is attributable to withdrawal itself.
| Trial | Population | N | Result | Identifiers |
|---|---|---|---|---|
| SURMOUNT-4 | Adults with obesity or overweight, without type 2 diabetes | 670 | Continued treatment maintained and modestly extended weight loss; withdrawal to placebo produced substantial regain | NCT04660643 · PMID 38078870 · DOI |
What can reduce regain, realistically?
The only intervention with randomised support for maintaining the result is continuing treatment. Beyond that, the general evidence on weight maintenance — sustained physical activity, adequate protein, structured monitoring — applies as it does after any weight loss, though none of it has been shown to match continued pharmacotherapy in this population.
Reduced-dose maintenance is under study and not yet verified here.
What the evidence shows
- Substantial regain after randomised withdrawal.
- Maintenance of loss with continued treatment.
- A consistent pattern across incretin withdrawal trials.
What the evidence does not show
- That any specific behavioural programme prevents regain after stopping.
- The precise trajectory for an individual.
- That compounded products behave the same way — none have been studied.
Related: Weight-regain evidence review · Stopping tirzepatide
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What does the regain trajectory look like in practice?
SURMOUNT-4 followed participants for 52 weeks after randomisation to placebo and recorded substantial regain accumulating over that period rather than an immediate rebound. Exposure declines over weeks given the five-day half-life, appetite returns as it does, and intake rises from there.
What the trial cannot provide is an individual trajectory. It reports group means over a fixed window, and it did not run long enough to establish where regain plateaus. Anyone quoting a precise percentage regained by a precise month is extrapolating beyond what was measured.
Why does framing regain as relapse cause practical harm?
Because it discourages honest conversation with prescribers. A person who believes regain reflects personal failure is less likely to report that they stopped, less likely to discuss restarting, and more likely to attempt unsupervised interventions. The randomised evidence directly contradicts the framing: participants regained after being assigned to stop, with nothing about their motivation changing at randomisation.
The accurate framing is that a treatment was withdrawn and the condition it was treating reasserted itself, which is what happens with chronic-condition treatments generally.
What does this page cover, and what does it deliberately leave out?
This page addresses SURMOUNT-4, timing and variability and maintenance implications, organised around the primary question of weight regain after stopping tirzepatide. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Surmount-4 | Covered on this page | Primary evidence |
| Timing | Covered on this page | Primary evidence |
| Variability and maintenance implications | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with a prescriber who knows your history |
What are the limits of what this page can tell you?
Every page on this site rests on a specific clinical evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a prescriber who knows your history.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
Any of the following would change what this page concludes:
- New primary evidence bearing directly on weight regain after stopping tirzepatide.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 8 technical terms this page uses, including DOI, PMID, compounded, half-life — in the specific sense used above.
| DOI | Digital Object Identifier. A persistent link to a specific published article that continues to resolve even if the journal reorganises its website. |
|---|---|
| PMID | PubMed Identifier. A number that locates the peer-reviewed publication of a study in the PubMed database. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| half-life | The time taken for the amount of drug in the body to fall by half. Tirzepatide's is roughly five days, which supports once-weekly dosing and means steady state takes several weeks. |
| incretin | A gut hormone released in response to food that amplifies insulin secretion. GIP and GLP-1 are the two principal human incretins, and the drug class that mimics them is named after them. |
| open-label | A trial in which participants and investigators know which treatment is being given. SURMOUNT-5 was open-label, a genuine limitation, though weight is an objective measurement less vulnerable to expectation than a self-reported outcome. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
| randomised withdrawal | A design in which everyone first receives the active drug, and only those who respond are then randomised to continue or stop. SURMOUNT-4 used this design, which is why its regain finding cannot be explained away by differences between groups. |
Frequently asked questions
Will I regain weight after stopping tirzepatide?
Substantial regain followed randomised withdrawal in SURMOUNT-4. Individual results vary.
How quickly does regain happen?
It accumulated over the 52-week randomised withdrawal period; the trial does not support a precise personal timeline.
Does regain mean the treatment failed?
No. It reflects the return of appetite signalling once the drug is withdrawn.
Can a lower dose prevent regain?
SURMOUNT-MAINTAIN answered this in 2026: Reducing to 5 mg maintained -16.6% bodyweight reduction versus -21.9% on the maximum tolerated dose and -9.9% on placebo (SURMOUNT-MAINTAIN, Lancet 2026). A reduced dose held most but not all of the result.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.